南新制药
(688189)
| 流通市值：17.01亿 | | | 总市值：17.01亿 |
| 流通股本：2.74亿 | | | 总股本：2.74亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 226,570,852.23 | 190,787,407.04 | 111,835,236.68 | 744,601,965.89 |
| 营业收入 | 226,570,852.23 | 190,787,407.04 | 111,835,236.68 | 744,601,965.89 |
| 二、营业总成本 | 217,984,472.13 | 150,223,118.7 | 89,089,221.39 | 628,167,166.97 |
| 营业成本 | 96,591,159.85 | 76,242,667.79 | 46,254,672.74 | 113,738,277.1 |
| 税金及附加 | 3,984,907.8 | 3,328,498.08 | 1,559,205.44 | 10,243,350.2 |
| 销售费用 | 63,868,011.29 | 41,889,003.81 | 28,765,178.83 | 370,945,370.73 |
| 管理费用 | 27,988,513.44 | 15,388,186.95 | 6,261,182.38 | 53,385,073.75 |
| 研发费用 | 26,325,369.38 | 14,799,006.3 | 6,826,875.34 | 74,863,912.65 |
| 财务费用 | -773,489.63 | -1,424,244.23 | -577,893.34 | 4,991,182.54 |
| 其中:利息费用 | 3,536,656.5 | 2,577,462.05 | 1,319,817.83 | 15,248,017.68 |
| 其中:利息收入 | 5,454,544.72 | 5,100,712.72 | 2,954,779.31 | 10,769,229.28 |
| 加:投资收益 | - | - | - | -14,911,680.82 |
| 资产处置收益 | - | - | - | 174,757.58 |
| 资产减值损失(新) | -2,780,228.97 | -2,899,873.3 | -2,932,820.04 | -8,803,136.36 |
| 信用减值损失(新) | -89,365,221.19 | -42,286,831.75 | -15,259,067.82 | -91,542,482.44 |
| 其他收益 | - | - | - | 6,059,974.22 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -83,559,070.06 | -4,622,416.71 | 4,554,127.43 | 7,412,231.1 |
| 加:营业外收入 | 1,388,539.67 | 1,212,681.32 | 529,859.87 | 1,019,616.86 |
| 减:营业外支出 | 645,528.7 | 535,326 | - | 824,593.1 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -82,816,059.09 | -3,945,061.39 | 5,083,987.3 | 7,607,254.86 |
| 减:所得税费用 | -144,036.72 | 1,689,404.19 | 406,741.49 | 1,652,483.47 |
| 六、净利润 | -82,672,022.37 | -5,634,465.58 | 4,677,245.81 | 5,954,771.39 |
| 持续经营净利润 | -82,672,022.37 | -5,634,465.58 | 4,677,245.81 | 5,954,771.39 |
| 归属于母公司股东的净利润 | -71,836,060.02 | -4,447,459.88 | 3,766,508.55 | 3,751,487.27 |
| 少数股东损益 | -10,835,962.35 | -1,187,005.7 | 910,737.26 | 2,203,284.12 |
| (一)基本每股收益 | -0.26 | -0.02 | 0.01 | 0.01 |
| (二)稀释每股收益 | -0.26 | -0.02 | 0.01 | 0.01 |
| 九、综合收益总额 | -82,672,022.37 | -5,634,465.58 | 4,677,245.81 | 5,954,771.39 |
| 归属于母公司股东的综合收益总额 | -71,836,060.02 | -4,447,459.88 | 3,766,508.55 | 3,751,487.27 |
| 归属于少数股东的综合收益总额 | -10,835,962.35 | -1,187,005.7 | 910,737.26 | 2,203,284.12 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-03-26 |
| 审计意见(境内) | | | | 标准无保留意见 |